Heart failure + new design + huge market

NuPulseCV is a medical device company specializing in the treatment of heart failure. Its core product is the iVAS, now branded as NuPulse Voyage.

The iVAS uses counterpulsation technology, working similarly to intra-aortic balloon counterpulsation (IABP), but with innovative improvements. The system uses a balloon pump implanted in the descending aorta. During diastole, the balloon inflates, increasing coronary perfusion; during systole, it rapidly deflates, reducing left ventricular afterload, thereby reducing cardiac workload and myocardial oxygen consumption. This synchronized counterpulsation mechanism effectively improves systemic blood circulation, providing mechanical support for a failing heart.

Unlike traditional IABPs, the iVAS uses a durable pump design, supporting long-term outpatient treatment. The system is implanted through a left subclavian artery incision, connected via a subcutaneous tunnel to an external drive unit, allowing patients to carry the portable drive unit for daily activities.

The iVAS system consists of three main parts.

Implantable Components: Includes a balloon-type mechanical pump with a capacity of approximately 50 mL, implanted through a minimally invasive incision in the descending aorta, placed via the left axillary or subclavian artery approach. This design avoids the open-chest surgery and cardiopulmonary bypass required by traditional LVADs. Percutaneous Connection Components: The pump body is connected to the external drive unit via a percutaneous lead, which exits through a subcutaneous tunnel, reducing the risk of infection. External Drive System: The portable external drive device weighs approximately 6 pounds (about 2.7 kg) and is equipped with a battery-powered system, supporting patient mobility and home discharge. Patients can intermittently disconnect the device under medical supervision, providing flexibility.

iVAS is suitable for patients with advanced heart failure, primarily used as a “transplant bridge,” “recovery bridge,” or “decision bridge.” Its greatest advantages are minimally invasive implantation and outpatient portability—patients do not need long-term hospitalization and can take the device home to await heart transplantation or recovery of cardiac function, significantly improving their quality of life.